Asia Pacific

HSBC has appointed Alexander Malloch as head of its international subsidiary banking (ISB) business in Thailand.

Korea Electric Power Corp (Kepco) made a remarkable return to the debt market on Monday, selling a $500m green bond as its first public dollar deal in 15 years.

Xi'an Municipal Infrastructure Construction Investment Group Corp has sealed a seven times subscribed bond to refinance an upcoming maturity. The deal was the first to price after China announced measures to curb local government debt by restricting new offshore issuance from their financing vehicles.

ESR-Reit, a real estate investment trust, has raised S$150m ($109.4m) from a combined placement and preferential offering of new units.

Maybank plans to return to the Chinese debt market on Wednesday with a Rmb2bn ($289m) Panda bond offering after a two-year hiatus. This time around, the Malaysian lender has roped in a policy bank as the trade’s lead underwriter.

Cooley has appointed capital markets lawyer Michael Yu as a partner in Hong Kong, as the firm continues ramping up its Asia presence.

Singapore’s Marina Bay Sands is seeking a total of S$4bn ($2.9bn) from the loan market, while also planning to extend its 2012 borrowing.

Xinyi Glass Holdings and Xinyi Group (Glass) Co sealed a HK$1.18bn ($150.3m) block trade of Xinyi Solar Holdings' shares on Monday after a lock-up expired on their positions in the company.

A UBS economist’s allegedly offensive comment about "Chinese pigs" has ensnared the Swiss bank in a series of unfortunate events, including being kicked off a planned dollar bond deal for China Railway Construction Corp. The backlash is overblown but serves as a warning for banks dealing with China.

Alibaba Group Holding’s board of directors has begun preparations for a planned IPO of up to $20bn in Hong Kong, proposing a stock split that will give the company flexibility for future capital market activities.

China Everbright Bank has become the latest Chinese lender to tap the offshore market for floating rate notes (FRN), raising $500m at an aggressive level on Monday.

Shanghai Junshi Biosciences’ shareholders have given the green light to the firm’s proposal to float primary stock on Shanghai’s new Nasdaq-style board, according to an exchange filing.